Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

nths, a promising early result. Patient follow-up in the trial is continuing.

"The data released today continues to reinforce the positive results seen across the five cancer trials to date assessing the potential of bavituximab in different treatment combinations across multiple tumor types," said Steven W. King, president and CEO of Peregrine. "We believe this data in aggregate shows the broad potential of this novel therapeutic compound for the treatment of solid tumors. We look forward to reporting further results from our ongoing bavituximab studies and to providing more details on future clinical development plans as they are finalized over the coming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab acts by binding to externalized PS on tumor blood vessels and inducing immune cell-mediated destruction of these blood vessels. It also restores the immune system's ability to recognize and resp
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... you may want to get screened and treated for ... According to a first-of-its-kind study in the October ... of the American Society of Anesthesiologists (ASA), patients with ... prior to surgery are less likely to develop serious ... "OSA is a common disorder that affects millions and ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry ... He is a 13-year veteran in the school, commercial and ... A-Z Bus Sales of Colton, California. While with A-Z Mr. ... top line revenues, profit and market penetration by double digits. ... to all-electric or plug-in hybrid vehicle conversions. They have ...
(Date:9/23/2014)... Carbon nanotubes serve as bridges that allow electrical ... patches invented at Rice University and Texas Children,s ... Jacot and chemical engineer and chemist Matteo Pasquali ... nanotubes. The patches are made of a sponge-like ... body,s extracellular matrix. , The nanotubes overcome a ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
Breaking Medicine News(10 mins):Health News:New research suggests sleep apnea screening before surgery 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2
... 2010 -- The American College of Cardiology and ... Interventions has been accepted for coverage by Thomson ... the Journal Citation Reports. The Journal will receive ... "The Editorial Board and the American College of Cardiology ...
... According to a ... programs, such as Medicare and Medicaid, have prompted hospitals to shift costs to automobile insurance ... hospital bills prior to payment. , ... Malvern, PA (Vocus) April 23, 2010 -- According to a new study from ...
... ... lipoplasty will be discussed by leading experts at the Annual Meeting of the American ... Convention Center April 23-27, 2010. “Point/Counterpoint – Laser Lipoplasty – Hype or Useful ... and Jeffrey M. Kenkel, MD. , ...
... at risk for facial deformities, poor grades, dentists say ... the mouth instead of the nose can lead to ... mouth breathers, most often children with allergies, have problems ... size, weight, sleep and even school performance, a recent ...
... INDIANAPOLIS Structural and functional congenital cardiovascular abnormalities present ... defects encountered in live births. Nearly half a million ... ranging in severity from relatively simple issues, such as ... severe malformations, including complete absence of one or more ...
... ... will be pleased with the final result, there is a small chance ... The realities of revision in rhinoplasty will be discussed by leading experts ... Aesthetic Plastic Surgery (ASAPS), being held at the Gaylord National Hotel and ...
Cached Medicine News:Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 2Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 3Health News:Hospital Cost Shifting Adds to Auto Injury Claim Costs 4Health News:Laser Lipoplasty: Cutting Through the Hype 2Health News:Laser Lipoplasty: Cutting Through the Hype 3Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 2Health News:Allergy-Linked Mouth Breathing Spells Trouble for Kids 3Health News:New strategies to improve treatment and avert heart failure in children 2Health News:New strategies to improve treatment and avert heart failure in children 3Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 2Health News:Chasing Perfection in the Nose: Revision Rhinoplasty 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: